APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 262 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $230,149 | -49.1% | 6,051 | +21.8% | 0.00% | -100.0% |
| Q2 2023 | $452,409 | -51.8% | 4,969 | -65.1% | 0.00% | -50.0% |
| Q1 2023 | $938,847 | +463.5% | 14,237 | +338.2% | 0.00% | – |
| Q4 2022 | $166,603 | -20.3% | 3,249 | +6.9% | 0.00% | – |
| Q3 2022 | $209,000 | +74.2% | 3,040 | +14.0% | 0.00% | – |
| Q2 2022 | $120,000 | -9.1% | 2,667 | +2.4% | 0.00% | – |
| Q1 2022 | $132,000 | -16.5% | 2,605 | -22.1% | 0.00% | – |
| Q4 2021 | $158,000 | +19.7% | 3,346 | -16.4% | 0.00% | – |
| Q3 2021 | $132,000 | -5.0% | 4,001 | +80.8% | 0.00% | – |
| Q2 2021 | $139,000 | +46.3% | 2,213 | +0.3% | 0.00% | – |
| Q1 2021 | $95,000 | -27.5% | 2,206 | -3.9% | 0.00% | – |
| Q4 2020 | $131,000 | +79.5% | 2,296 | -4.2% | 0.00% | – |
| Q3 2020 | $73,000 | -6.4% | 2,396 | 0.0% | 0.00% | – |
| Q2 2020 | $78,000 | +14.7% | 2,396 | -6.3% | 0.00% | – |
| Q1 2020 | $68,000 | – | 2,556 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |